A four-year South African clinical trial resumes this week in what promises to be a possible vaccine to prevent HIV.
The nationwide trial is comprised of over 5400 South African volunteers to determine the efficacy of what could be a ground-breaking development.
According to President of the SA Medical Research Council Professor Glenda Gray, the trial and monitoring period will involve men and women between the age of 18 to 35.
The vaccine is called HCT702... This is 5400 people in 15 sites in South Africa ranging from Umtata to Soshanguwe, from KwaZulu-Natal to Western Cape, a few sites is Gauteng.— Professor Glenda Gray, SAMRC
She revealed highly stringent safety measures that have been put in place, emphasising the importance of the trail being effective to fight the ongoing scourge, she says.
Professor Gray shared more details on the recent developments, which could usher in a new era in ground-breaking HIV treatment and prevention.
Hopefully, this will induce a new response that will protect people from HIV acquisition.— Professor Glenda Gray, SAMRC
Listen to more details of this groundbreaking trial for an HIV vaccine below: